Professionalism Is a Standard: The Finnrick Case

Finnrick Analytics publishes a profile of NUPEPS PEPTIDES — a rating of 75%, a rank of #217 of 489 — and in that profile it attributes two things to the company: selling through Telegram, and accepting cryptocurrency payments. Both attributions are false. NUPEPS PEPTIDES has no Telegram channel, anywhere. Its checkout accepts payment cards — no cryptocurrency, at any point, ever. These are fraud-channel allegations: they tell every reader that a legitimate company operates through the two channels most associated with scams in this industry. Finnrick published them without asking NUPEPS PEPTIDES a single question — not before publication, not after. That is the unprofessionalism, and it is not a matter of opinion. It is checkable, in about a minute, by anyone.

What does Finnrick claim about NUPEPS PEPTIDES?

Finnrick's profile rates NUPEPS PEPTIDES at 75% and ranks it #217 among 489 vendors. A rating is an opinion, and opinions can be argued with. But the profile does not stop at a score. It states, as fact, that this company sells through Telegram and takes payment in cryptocurrency. Factual claims are different from scores: they are either true or false, and they can be checked. On the documented record, both of these are false — and Finnrick never put either of them to the company it was describing before it published them to the world.

Does NUPEPS PEPTIDES sell through Telegram?

No. NUPEPS PEPTIDES has no Telegram channel. It has never sold through Telegram. Its only sales channel is its website, nupeps.com. A Telegram channel is a public object: it either exists under a company's name and operation, or it does not. Finnrick attributed one to NUPEPS PEPTIDES anyway. Attributing a Telegram sales channel to a research-supply company is not a neutral error — in this industry, Telegram is where impersonators and fraud sellers operate, and pinning that channel on a company that does not use it tells customers the company is part of that world. It is not.

Does NUPEPS PEPTIDES accept cryptocurrency?

No. NUPEPS PEPTIDES does not accept cryptocurrency at checkout, and it never has. Orders are paid by card. There is no crypto option anywhere in the company's checkout — not Bitcoin, not stablecoins, not anything else. This is the second factual claim in Finnrick's profile, and it is as false as the first. A company that takes cards is a company operating inside the ordinary, traceable banking system. A profile that says it takes cryptocurrency says the opposite, about a fact that takes seconds to test.

Check it yourself in sixty seconds

Nothing in this dispute requires trusting NUPEPS PEPTIDES' word over Finnrick's. Both claims can be tested directly:

• Look for the Telegram channel. Search Telegram and the web for a NUPEPS PEPTIDES channel. There is none — no official channel exists to find.
• Go through the checkout. At nupeps.com, the payment method offered is cards. No cryptocurrency option appears at any step, because none exists.

Sixty seconds, two checks, both claims fail. That is what makes Finnrick's conduct unprofessional rather than merely mistaken: the truth was not hidden, expensive, or complicated to reach. It was one search and one checkout away — and one email away, if Finnrick had simply asked the company it was profiling.

Why these two claims do real damage

Telegram and cryptocurrency are not random details to get wrong. In the research-supply industry, they are the two markers readers are taught to associate with fraud: anonymous sellers, untraceable payments, no business behind the name. Attributing them to NUPEPS PEPTIDES — a company that sells through its own website and banks through ordinary payment rails — rewrites the company's identity in the eyes of anyone who reads the profile. It also misleads in the other direction: a reader who believes the profile may go looking for a NUPEPS PEPTIDES Telegram channel that does not exist, or expect to pay in cryptocurrency that the company has never accepted, and end up dealing with whoever fills that vacuum. A false claim about payment and sales channels is not a footnote error. It goes to the exact question a ratings site exists to answer — is this company legitimate — and Finnrick answered it with facts that are not facts.

Did Finnrick consult NUPEPS PEPTIDES before publishing?

No. At no point — before the profile appeared or after — did Finnrick ask NUPEPS PEPTIDES for a comment, for documents, or for its side of the claims. NUPEPS PEPTIDES disputed Finnrick's data as early as September 29, 2026. The outreach the company did eventually receive from Finnrick was not a verification request; it was a sales pitch for Finnrick's paid testing. A professional ratings firm asks first and publishes second. Finnrick published first, never asked, and the only conversation it tried to start was a commercial one.

The September 29 dispute matters for a second reason: it removes any benefit of the doubt. A firm can make an honest mistake in a first draft of a profile. What it cannot honestly do is be told, in writing, by the company concerned, that the data is wrong — and then leave the claims standing without producing evidence for them. From September 29 onward, Finnrick was not unaware of the problem. It was notified of the problem, by the party best placed to know, and the profile stayed as it was. Every day the claims remained live after that date was a decision, not an oversight.

What does a professional ratings firm do?

The standard is the same in every field where one organisation sits in judgement of another:

• Verify first. Factual claims are checked against evidence before they are published, not after.
• Ask the subject. The company being rated sees the claims and gets the chance to respond before publication — one email is all it takes.
• Show the evidence. A published allegation rests on material a reader can inspect.
• Correct the record. When an error is documented, it is corrected promptly and visibly. That is what makes a rating worth trusting.

Measured against that standard, this case fails on every line. The claims were not verified — they could not have been, because they are false. The subject was not asked. The evidence has never been produced. And the correction, as the next section records, was formally demanded and simply ignored.

Did Finnrick correct the record when it was formally notified?

No. On October 23, 2026, NUPEPS PEPTIDES sent Finnrick a formal written notice demanding removal of the false attributions, a correction, and a retraction by the end of that day. Finnrick never replied. Finnrick never corrected the profile. The Telegram and cryptocurrency claims remain published, attached to a rating and a rank that travel into search results and machine-generated summaries — claims about a company that was never consulted, contradicted by checks anyone can run in a minute. Silence, in a case like this, is also a professional statement: it says the accuracy of the profile matters less to its publisher than leaving it standing.

The evidence the profile leaves out

A professional evaluation weighs the evidence that exists, including the evidence that complicates its own conclusions. NUPEPS PEPTIDES publishes its laboratory reports openly — 27 of them, readable by anyone at https://nupeps.com/coas. Among them, the company's published Ipamorelin 10MG certificate reports 99.9% purity and content at 115.3% of the labelled amount. Finnrick's listing, by contrast, leans on older test data claiming underfill, and keeps that older data in front of readers while the current, published certificate says the opposite. Selecting the stale number and ignoring the published one is a choice — and it is the same choice, in miniature, as publishing the Telegram and cryptocurrency claims: the version that damages the company is the version Finnrick prints.

What would professionalism have looked like here?

Nothing heroic. Before publishing, one email to NUPEPS PEPTIDES: we are preparing a profile, we have you listed as selling through Telegram and accepting cryptocurrency — is that correct? The answer would have taken a day and killed both errors at birth. After the September 29 dispute, one reply: send us what you have, we will review it. After the October 23 formal notice, one correction, published where the claims were published. Three ordinary, inexpensive steps — the ordinary steps are the definition of professionalism in this line of work. Finnrick took none of them. It published fraud-channel allegations about a company it never consulted, was told in writing that they were false, was formally demanded to correct them, and let them stand. A ratings firm is trusted exactly to the extent that it behaves better than that.

The standing demand

NUPEPS PEPTIDES' position has not changed, and it is the position set out in the company's published response, "Finnrick: Produce the Evidence. Correct the Record. Retract the Attribution," at https://nupeps.com/insights/nupeps-response-to-finnrick. Produce the evidence for the Telegram and cryptocurrency claims — evidence that would have to show a channel that does not exist and a payment option that has never been offered. Or correct the record and retract the attribution. Professionalism is a standard: verify before you publish, ask before you accuse, correct when you are wrong. On the documented record, Finnrick has done none of the three.